NCT07456774Enrolling by invitation
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
A Retrospective Database Study to Compare Cardiovascular and Renal Outcomes of Ozempic® (OW Semaglutide) Versus Other Anti-Diabetic Drugs in Chinese T2D Patients
Source: ClinicalTrials.gov · Last updated 20 May 2026
Brief summary (registry, in English)
The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients. This is a retrospective study, and participants had received Ozempic or any other anti-diabetic medications.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 100000 (estimated)
- First submitted
- 9 Feb 2026
- Start date
- 13 Feb 2026
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Type 2 diabetes
- NCT number
- NCT07456774
What you commit to
- Study type: Observational
- Planned participants: 100000
- From 13 Feb 2026 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have used any same anti-diabetic medications as the index treatment within 6 months before index date (e.g., patient prescribed with any Ozempic® during baseline will be excluded if the index drug is a Ozempic®)
Other illness
- Patients with any diagnosis record of type 1 diabetes or gestational diabetes during whole study period.
Other
- Patients who were pregnant during the whole study period.
- Patients who participated in any clinical trials during the whole study period.
- Patients who were diagnosed with medullary thyroid carcinoma or multiple endocrine neoplasia type II (MEN2) during the whole study period.
Who the study is looking for
- Participants had at least one prescription for Ozempic® or other interested anti-diabetic medications during the index identification period.
- Participants had at least one diagnosis of T2D, and had at least one of the three following T2D clinical evidence any time before or on the index date
- Participants had at least 1 all-cause visit record any time after 6 months post-index date.
- At least 18 years old at the index date.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NIS- Tianjin Medical University Chu Hsien-I Memorial Hospital-Department of Endocrinology Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.